Posted by Michael Wonder on 11 Jul 2025
Transcend Therapeutics receives breakthrough therapy designation for TSND- 201 (methylone) for the treatment of PTSD
10 July 2025 - Company planning to initiate Phase 3 program.
Transcend Therapeutics today announced that the US FDA has granted breakthrough therapy designation to TSND-201 (methylone) for the treatment of post-traumatic stress disorder.
